| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4647477
Max Phase: Preclinical
Molecular Formula: C17H26N4O4
Molecular Weight: 350.42
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: CC(C)(C)CC(=O)NC(C)(C)CC(=O)Nc1cncc(C(=O)O)c1N
Standard InChI: InChI=1S/C17H26N4O4/c1-16(2,3)6-13(23)21-17(4,5)7-12(22)20-11-9-19-8-10(14(11)18)15(24)25/h8-9H,6-7H2,1-5H3,(H2,18,19)(H,20,22)(H,21,23)(H,24,25)
Standard InChI Key: WPEBHSXZZQIWLF-UHFFFAOYSA-N
Associated Targets(Human)
T1R2/T1R3 282 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 350.42 | Molecular Weight (Monoisotopic): 350.1954 | AlogP: 2.02 | #Rotatable Bonds: 6 |
| Polar Surface Area: 134.41 | Molecular Species: ZWITTERION | HBA: 5 | HBD: 4 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 1.71 | CX Basic pKa: 9.33 | CX LogP: -0.18 | CX LogD: -0.19 |
| Aromatic Rings: 1 | Heavy Atoms: 25 | QED Weighted: 0.62 | Np Likeness Score: -0.76 |
References
| 1. Yamada K, Matsumoto R, Suzuki Y, Mori S, Kitajima S.. (2020) Design, synthesis and evaluation of unnatural peptides as T1R2/T1R3 PAMs., 30 (8): [PMID:32063432] [10.1016/j.bmcl.2020.127000] |
Source
Source(1):